Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 5458514

Next Previous
Drug Profile

GSK 5458514

Alternative Names: GSK-5458514

Latest Information Update: 18 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GSK
  • Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 12 Jun 2025 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory, Combination therapy) in USA, Japan (Parenteral) (NCT06990880)
  • 12 Jun 2025 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Monotherapy, Hormone refractory) in Japan, USA (Parenteral) (NCT06990880)
  • 25 May 2025 GlaxoSmithKline plans a phase-I/II trial for Prostrate cancer (Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy, Hormone refractory) in June 2025 (Parenteral), (NCT06990880)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top